Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 5Gliosarcoma 2Brain Neoplasms 2Recurrence 1Prostatic Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Metatropic dwarfism 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × Cilengitide × Clear all
NCT00093964 2019-04-16

Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)

EMD Serono

Phase 2 Completed
81 enrolled 21 charts
CNS

Brain Neoplasms, Glioblastoma

NCT00112866 2017-06-14

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Terminated
30 enrolled 10 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡